UAB 1923: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) study

Grant

Awarded By

Total Award Amount

  • 177075.00

    • Direct Costs

  • 136212.00

    • Sponsor Award Id

    • Contributor

  • Amitkumar Mehta M.D.   Principal Investigator  
  • Gaurav Goyal   Investigator  
  • Luciano Costa M.D., Ph.D.   Investigator  
  • Mayur Narkhede   Investigator  
  • Pankit Vachhani   Investigator